Osteoprotegerin ligand: A regulator of immune responses and bone physiology

Immunology Today

Volumn 21, Issue 10, 2000, Pages 495-502

  Kong, Young Yun ^a   Boyle, William J ^b   Penninger, Josef M ^c  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b AMGEN INC   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLUCOCORTICOID; GLYCOPROTEIN GP 39; GROWTH FACTOR; HORMONE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROSTAGLANDIN; TUMOR NECROSIS FACTOR;

ARTHRITIS; B LYMPHOCYTE; BONE ATROPHY; BONE DISEASE; BONE METABOLISM; BONE REMODELING; CELL ACTIVATION; CELL INTERACTION; CELL MATURATION; CELL SURVIVAL; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; IMMUNOREGULATION; NONHUMAN; ORGANOGENESIS; OSTEOCLAST; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE;

EID: 0033791573     PISSN: 01675699     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5699(00)01718-7     Document Type: Note

References (62)

1. Cell biology of the osteoclast
2. Role of cytokines in rheumatoid arthritis
3. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis
4. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
5. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells
6. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
7. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
8. Evidence for a role of a tumor necrosis factor-alpha (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival
9. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
10. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
11. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
12. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis
13. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
14. RANK is essential for osteoclast and lymph node development
15. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
16. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis
17. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
18. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin
19. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
20. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1β, TNF-α, PTH, PTHrP, and 1,25(OH)2D3
21. TRANCE [tumor necrosis factor (TNF)-related activation-induced cytokine], a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor
22. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40
23. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin
24. Selective disruption of lymphotoxin ligands reveals a novel set of mucosal lymph nodes and unique effects on lymph node cellular organization
25. Distinct roles in lymphoid organogenesis for lymphotoxins α and β revealed in lymphotoxin β-deficient mice
26. Abnormal development of secondary lymphoid tissues in lymphotoxin β-deficient mice
27. Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers
28. Lymph node genesis is induced by signaling through the lymphotoxin β receptor
29. The lymphotoxin β receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues
30. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2
31. Peyer's patch organogenesis is intact, yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor
32. + cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells
33. Selection of the T cell repertoire
34. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity
35. Dendritic cells and the control of immunity
36. Dendritic cells capable of stimulating T cells in germinal centres
37. + T cells
38. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II
39. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression
40. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
41. Consequences of cell death. Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
42. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src
43. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo
44. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells
45. + T cells
46. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation
47. The immune responses in CD40-deficient mice: Impaired class switching and germinal center formation
48. Mice deficient for the CD40 ligand
49. + cytotoxic T lymphocytes
50. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells
51. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles
52. + T cell-mediated cytotoxicity
53. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
54. IL-1α β blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation
55. Vertebral compression fractures at the onset of acute lymphoblastic leukemia in a child
56. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy
57. Bone mineral density and bone metabolism in diabetes mellitus
58. Enhanced prostanoid release from J monocytes of patients with rheumatoid arthritis and active systemic lupus erythematosus
59. Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids
60. How can we improve the treatment of bone metastases further?
61. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord
62. Functional human T-cell immunity and osteoprotegerin-ligand (OPG-L) control alveolar bone destruction in periodontal infection